Clinical Trials · NCT03947762
Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.
- Phase
- N/A
- Recruitment status
- Terminated
- Sponsor
- Ipsen
- Enrollment
- 54
- Start date
- Jul 2019
- Locations
- 46 sites, Portugal, Spain
- Primary endpoint
- Progression-free survival (PFS) rate at 24 months